Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.37 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207428 | 0.83 | ALDH1A1 (0.41) | NOS1METAP2CSNK2A1JAK2PDPK1 | |
| SCHEMBL207659 | 0.75 | F7 (0.42) | NOS1AHRNR4A2BACE1DYRK1A | |
| SCHEMBL5981619 | 0.75 | DYRK1A (0.42) | CSNK2A1CYP2A6DYRK1AHTTKDR | |
| SCHEMBL208893 | 0.75 | KDM4E (0.36) | METAP2AHRCYP1A2CYP2C19HTT | |
| SCHEMBL211832 | 0.75 | KMT2A (0.38) | NOS1CYP1A2CYP2C19HTTCHEK1 | |
| SCHEMBL7221951 | 0.75 | ALDH1A1 (0.42) | PDPK1PRKD3FLT3MAP4K2AURKB | |
| SCHEMBL208047 | 0.73 | FLT3 (0.46) | NOS1METAP2CSNK2A1JAK2PDPK1 | |
| SCHEMBL7271829 | 0.71 | KIF11 (0.36) | NOS1CYP2A6CYP1A2ALDH1A1LMNA | |
| SCHEMBL7409270 | 0.71 | DYRK3 (0.43) | JAK2BACE1DYRK1AMAP4K4CLK2 | |
| SCHEMBL142611 | 0.71 | PKM (0.41) | METAP2BACE1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | claimed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | claimed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | claimed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | claimed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | claimed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | claimed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-1060178-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER (US) | 2003-09-03 | — | — | EP | claimed |
| US-6610707-B1 | Moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage. | PFIZER INC. | 2003-08-26 | — | — | US | claimed |
| EP-1060178-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | claimed |
| CN-111372924-B | Novel one-pot homogenization process for large-scale manufacture of 2-substituted benzimidazoles | 埃科莱布美国股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-0343894-A1 | Benzamide protease inhibitors | PFIZER INC. (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4874864-A | ANTIPLASMIN, ANTITHROMBIN AGENTS | PFIZER INC. (US) | 1989-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | NOS1 324/4885METAP2 4603/4885CSNK2A1 3768/4885 |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | NOS1 728/4885METAP2 3181/4885CSNK2A1 1716/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | NOS1 412/4885METAP2 3854/4885CSNK2A1 4580/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | NOS1 151/4885METAP2 4459/4885CSNK2A1 4596/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | NOS1 151/4885METAP2 4459/4885CSNK2A1 4596/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | NOS1 151/4885METAP2 4459/4885CSNK2A1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.